Short-Course SBRT: Standard of Care in Prostate Cancer?

SAN DIEGO — With just five fractions of stereotactic body radiation therapy (SBRT), men with low- or intermediate-risk prostate cancer can have 5-year disease control as good as that provided by conventional external-beam radiation therapy delivered at higher doses in 20-39 fractions, according to new data from the phase 3 randomized PACE-B trial. Overall, the 5-year event-free survival rates were […]
» Read more